Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 10;12(4):342.
doi: 10.3390/pharmaceutics12040342.

Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates

Affiliations

Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates

Hannes Lengauer et al. Pharmaceutics. .

Abstract

Tenofovir alafenamide fumarate (TAF) is the newest prodrug of tenofovir that constitutes several drug products used for the treatment of HIV/AIDS. Although the solid-state properties of its predecessor tenofovir disoproxil fumarate have been investigated and described in the literature, there are no data in the scientific literature on the solid state properties of TAF. In our report, we describe the preparation of two novel polymorphs II and III of tenofovir alafenamide monofumarate (TA MF2 and TA MF3). The solid-state structure of these compounds was investigated in parallel to the previously known tenofovir alafenamide monofumarate form I (TA MF1) and tenofovir alafenamide hemifumarate (TA HF). Interestingly, the single-crystal X-ray diffraction of TA HF revealed that this derivative exists as a co-crystal form. In addition, we prepared a crystalline tenofovir alafenamide free base (TA) and its hydrochloride salt (TA HCl), which enabled us to determine the structure of TA MF derivatives using 15N-ssNMR (15N-solid state nuclear magnetic resonance). Surprisingly, we observed that TA MF1 exists as a mixed ionization state complex or pure salt, while TA MF2 and TA MF3 can be obtained as pure co-crystal forms.

Keywords: X-ray diffraction; co-crystal; polymorphism; salt; ssNMR; tenofovir alafenamide fumarate.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Chemical structure of tenofovir and its prodrug fumarate derivatives.
Figure 2
Figure 2
Powder X-ray diffraction patterns of tenofovir alafenamide fumarate derivatives. Red: TA HF; Blue: TA MF1; Green: TA MF2; Magenta: TA MF3.
Figure 3
Figure 3
Thermal ellipsoid figures of (a) TA and (b) TA HF drawn at the 30% probability level. The asymmetric unit of TA HF contains one tenofovir alafenamide molecule and half of a molecule of fumaric acid. The disorder of the phenyl and isopropyl groups in TA HF is omitted for clarity. Hydrogen bonds are drawn with dashed blue lines.
Figure 4
Figure 4
Hydrogen bond architecture in the TA crystal. (a) The interactions involving adenine moieties; (b) Wavy layered structure along the b axis; (c) Packing of layers along the c axis (arbitrary colors). Hydrogen bonds are drawn with dashed blue lines. Hydrogen atoms not involved in the shown motif have been omitted for clarity.
Figure 5
Figure 5
Hydrogen bond architecture in the TA HF co-crystal. (a) Hydrogen bonding between both carboxylic groups of fumaric acid and two adjacent tenofovir alafenamide molecules; (b) Hydrogen bonding between adjacent tenofovir alafenamide molecules and intramolecular hydrogen bonding. Hydrogen bonds are drawn with dashed blue lines. Hydrogen atoms not involved in the shown motif have been omitted for clarity. The disorder of the isopropyl and phenyl groups is omitted for clarity.
Figure 6
Figure 6
15N CP MAS NMR (15N cross-polarization magic angle spinning nuclear magnetic resonance) spectra of (a) TA, (b) TA HCl and (c) TA HF.
Figure 7
Figure 7
15N LG-CP MAS NMR (Lee-Goldburg cross-polarization magic angle spinning nuclear magnetic resonance) spectra of (a) TA and (b) TA HCl. Both spectra were acquired using a relaxation delay of 2 s and ca. 40,000 scans. The relative integral value of protonated purine nitrogen is reported with respect to the integral region of amine nitrogen, which was arbitrarily set at 100.
Figure 8
Figure 8
15N LG-CP MAS NMR spectra of (a) TA MF1 and (b) TA MF3. Both spectra were acquired using a relaxation delay of 1 s and ca. 200,000 scans. The relative integral value of protonated purine nitrogen is reported with respect to the integral region of amine nitrogen, which was arbitrarily set at 100.
Figure 9
Figure 9
Superposition showing the difference in conformation of tenofovir alafenamide molecules in TA (red) and TA HF (blue). The disorder on the isopropyl and phenyl groups is omitted for clarity.
Figure 10
Figure 10
15N LG-CP MAS NMR spectra of different samples of TA MF1: (a) the majority of samples contains salt species, (b) the sample contains approximately 30% of salt species and (c) the sample contains approximately 20% of salt species. All spectra were acquired using a relaxation delay of 1 s and ca. 200,000 scans. The relative integral value of protonated purine nitrogen is reported with respect to the integral region of amine nitrogen, which was arbitrarily set at 100.

Similar articles

Cited by

References

    1. The Top 10 Causes of death. [(accessed on 12 March 2020)]; Available online: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
    1. Global Factsheets 2018 HIV and AIDS Estimates. [(accessed on 12 March 2020)]; Available online: http://aidsinfo.unaids.org/
    1. Kinch M.S., Patridge E. An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs. Drug Discov. Today. 2014;19:1510–1513. doi: 10.1016/j.drudis.2014.05.012. - DOI - PubMed
    1. Blanco J.L., Whitlock G., Milinkovic A., Moyle G. HIV integrase inhibitors: A new era in the treatment of HIV. Expert Opin. Pharmacother. 2015;16:1313–1324. doi: 10.1517/14656566.2015.1044436. - DOI - PubMed
    1. Caplan M.R., Daar E.S., Corado K.C. Next generation fixed dose combination pharmacotherapies for treating HIV. Expert Opin. Pharmacother. 2018;19:589–596. doi: 10.1080/14656566.2018.1450866. - DOI - PubMed